marketing wars over the new sleeping pills

September 2005

You'll see marketing wars over the new sleeping pills... Lunesta, Rozerem, Ambien CR, and then indiplon next year.

Lunesta (eszopiclone) is making a big splash now to get a head start. It's the first one approved for long-term use...but it has a bitter aftertaste in up to 30% of patients.

Rozerem (ro-ZER-um) will be out this month. It's the first in a new class...melatonin receptor agonists.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

marketing wars over the new sleeping pills
Diabetes two new pending drugs for diabetes, Pargluva (muraglitazar) and Exubera (inhaled insulin)
Women's Health Ortho Evra contraceptive patch and reports of deaths due to blood clots
Women's Health which drugs decrease efficacy of oral contraceptives (OCs)
Infectious Diseases CDC just released new guidelines for the 2005-2006 flu season
a new inhaled corticosteroid called Asmanex
appropriate use of long-acting inhaled beta-agonists for asthma
alternatives to pseudoephedrine
Cholesterol There's confusion about all the different formulations of fenofibrate
Dermatology iPledge will restrict Rxs for Accutane
Supplements the question of whether echinacea is useful for the common cold
Supplements how ginkgo interacts with other drugs
Pediatrics whether autism is caused by thimerosal in vaccines
Patient Privacy/HIPAA what HIPAA allows when discussing drug therapy
Practice higher risk of hypertension in women taking chronic NSAIDs or acetaminophen

marketing wars over the new sleeping pills

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Table of Contents